Project Grant R01HL168278

Award Date 7/15/24
Completion Date 6/30/29
Dollars Obligated $1.2M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Denver, CO 80206, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in guiding alveolar epithelial regeneration following lung injury. The key objectives are to determine how aerocyte-derived signaling, particularly the angiocrine factor R-spondin3, regulates alveolar...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a therapeutic strategy to replace a failed component of the macrophage lung injury response and enable healing in patients with bacterial pneumonia. The $656,988 award, with a period of performance from August 1, 2025 to April 30, 2030, will be used by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $188,892 in funding to the University of Washington from August 1, 2025 to July 31, 2030. The project aims to determine the role of CD163+ blood monocytes and lung macrophages in the development of progressive pulmonary fibrosis, a chronic and debilitating lung disease. The research will leverage the university's expertise in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $683,564 to The Trustees of the University of Pennsylvania to conduct research on alveolar epithelial stress signaling in pulmonary fibrosis. The research aims to understand why a subset of alveolar type 2 (AT2) cells in the lung develop an "aberrant transitional" state and fail to fully differentiate, which may contribute to...
The University of Southern California received a $1,659,996 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on the role of the PDLIM2 protein in regulating alveolar macrophage function and its impact on lung immunity, inflammation, and diseases. The research aims to elucidate how alveolar macrophages, the primary immune cells in the lungs, are transformed to promote lung cancer, lung diseases, and increase...
This federal Project Grant award of $229,608, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research focused on understanding the role of pleural mesothelial cells in lung injury, repair, and regeneration. The primary awardee, Mayo Clinic, will conduct a series of lineage-tracing experiments in mouse models to investigate the recruitment and migration of pleural mesothelial cells in response to lung...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $831,755 over 5 years to New York University (NYU) to conduct research on the role of lung-resident macrophage subsets in regulating type 2 immune responses and trained immunity. The research aims to elucidate the distinct functions of different macrophage populations, particularly nerve- and...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the impact of acute lung injury on cell lineage behavior and its contribution to long-term changes affecting lung regeneration. The $701,795 award, with a project period from September 1, 2025 to June 30, 2029, will enable a multi-modal research approach at the University of Pennsylvania, including cell...
This federal Project Grant award of $744,880 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate how metabolic intermediates like lactate produced by alveolar epithelial type II (ATII) cells can shift the phenotype of alveolar macrophages towards an anti-inflammatory state during acute lung injury (ALI). The primary research objective is to delineate the protective mechanisms by which ATII...

REPARATIVE FUNCTIONS OF HUMAN AIRSPACE MACROPHAGE SUBSETS - PROJECT SUMMARY FOR LUNG HEALTH TO BE RESTORED AFTER INFLAMMATION, DEAD CELLS MUST BE REMOVED FROM THE AIRSPACES AND THE ALVEOLAR EPITHELIUM MUST BE REPAIRED. AIRSPACE MACROPHAGES (AM) HAVE BEEN IMPLICATED IN CLEARANCE OF APOPTOTIC CELLS, TERMED EFFEROCYTOSIS, AND IN ORCHESTRATING EPITHELIAL REPAIR. WHETHER ALL AM ARE CAPABLE OF THESE FUNCTIONS, OR WHETHER DISTINCT SUBSETS PERFORM SPECIALIZED ROLES FOLLOWING INFLAMMATION IS POORLY UNDERSTOOD. IN PREVIOUS STUDIES, WE LEVERAGED AN ENDOBRONCHIAL LIPOPOLYSACCHARIDE (LPS)-CHALLENGE MODEL OF ACUTE LUNG INFLAMMATION IN HEALTHY ADULTS TO OBTAIN HUMAN AM AND INVESTIGATE THEIR TRANSCRIPTIONAL SIGNATURES. USING SINGLE CELL RNA SEQUENCING, WE DISCOVERED THAT AFTER EXPOSURE TO LPS, THE AIRSPACES ARE DOMINATED BY RECRUITED AM. THESE RECRUITED AM CAN BE DIVIDED INTO TWO DISCRETE SUBSETS BASED, IN PART, ON THEIR EFFEROCYTIC AND REPARATIVE SIGNATURES. HOWEVER, THE CAUSAL MECHANISM BY WHICH EFFEROCYTOSIS IS LINKED TO REPARATIVE PROGRAMING OF AM IN HUMANS HAS NOT BEEN ESTABLISHED. THE PRIMARY OBJECTIVE OF THIS PROPOSAL IS TO IDENTIFY THE UNIQUE FUNCTIONS AND MOLECULAR DRIVERS OF AM SUBSETS DURING RESOLUTION OF INFLAMMATION AND ACTIVE LUNG REPAIR. BASED ON ANALYSIS OF TRANSCRIPTIONAL SIGNATURES AND OUR PRIOR STUDIES, WE POSTULATE THAT A SUBSET OF AM THAT CLOSELY RESEMBLE INTERSTITIAL MACROPHAGES (IMAM) ARE CHARACTERIZED BY TWO UNIQUE FUNCTIONS. FIRST, WE PROPOSE THAT IMAM ARE UNIQUELY PROGRAMED FOR EFFEROCYTOSIS. SECOND, WE HYPOTHESIZE THAT IMAM DRIVE REPAIR OF THE ALVEOLAR EPITHELIUM THROUGH PRODUCTION OF PARACRINE SIGNALING MOLECULES. THE PROPOSED STUDIES WILL INDEPENDENTLY TEST THE DEPENDENCE OF EFFEROCYTOSIS ON DRIVING THESE FUNCTIONS. WE WILL USE PRIMARY AM OBTAINED FROM ENDOBRONCHIAL LPS-CHALLENGE OF RESEARCH PARTICIPANTS AND CUTTING-EDGE ORGANOTYPIC CO-CULTURE SYSTEMS IN THE FOLLOWING THREE SPECIFIC AIMS: 1) TEST THE HYPOTHESIS THAT IMAM ARE SPECIALIZED FOR EFFEROCYTOSIS. 2) TEST THE HYPOTHESIS THAT IMAM PROMOTE ALVEOLAR EPITHELIAL REPAIR. 3) DETERMINE WHETHER EFFEROCYTOSIS IS REQUIRED FOR REPARATIVE PROGRAMING OF HUMAN AM.

Posted 7/12/24